Novo Nordisk Shares Plunge After Company Predicts 2026 Sales and Profit Declines
Novo Nordisk's stock fell sharply after the company warned that both sales and operating profit would decline in 2026, citing lower drug prices in the United States. The 16% drop in shares erased roughly $50 billion in market value and marked a significant reversal for the obesity drug maker's market position.